Non-stimulant ADHD medications, such as atomoxetine and guanfacine, provide effective alternatives to stimulants, addressing ...

The same year, Shire entered into a partnership with Shionogi & Co to co-develop Vyvanse and Intuniv in Japan. "Shire began broadening into rare diseases with the acquisition of orphan drug ...